Articles related to Oncology, Radiation

A phase 3 trial comparing doxorubicin-trabectedin combination therapy to doxorubicin alone in advanced leiomyosarcoma patients demonstrated a median overall survival of 33 months versus 24 months, respectively.

The TOPAZ-1 trial demonstrates that adding durvalumab to standard chemotherapy significantly improves overall survival in patients with advanced biliary tract cancer, potentially establishing a new first-line treatment option for this difficult-to-treat malignancy.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

Nearly 70% of 340B contract pharmacies are now associated with pharmacy benefit managers, potentially shifting the program’s focus away from its original intent of supporting safety-net providers.

The loss of two oncology residents in a plane crash has left a significant void in cancer care at a major oncology center in Paraná, Brazil, highlighting the critical role of specialized medical professionals in smaller communities.